Metabolic · research grade
TZ-GLP2
GIP/GLP-1 dual agonist. Independently verified and released in the United States.
Research & references
Tirzepatide (PR-GLP2) →A dual agonist at the GIP and GLP-1 receptors.Source 1 In the SURMOUNT-1 trial, mean weight change at 72 weeks was −20.9% on 15 mg versus −3.1% on placebo, with mostly mild-to-moderate gastrointestinal adverse events during dose escalation.Source 2 The same molecule is the active ingredient of an approved prescription medicine; material supplied here is research-grade, is not that product, and is not supplied for human use.
Specification
Form
Lyophilized powder, clear vial
Size
20 mg
Purity
99.71% (RP-HPLC, 214 nm)
Identity
ESI-MS to ±1 Da
Current lot shipping
LOT TIR-26-020
Storage
36–46 °F (reconstituted), protected from light
Release
Released on Freedom Diagnostics results
Intended use
Laboratory research only